April 10, 2017, Pregnant
women or women in the postpartum period with acute-onset, severe
systolic hypertension, severe diastolic hypertension, or both, require
urgent antihypertensive therapy. The American College of Obstetricians
and Gynecologists (ACOG) has issued a committee opinion on this topic,
offering both recommendations and conclusions, including:
- Introducing standardized, evidence-based clinical guidelines for the management of patients with preeclampsia and eclampsia has been demonstrated to reduce the incidence of adverse maternal outcomes.
- Close maternal and fetal monitoring by a physician and nursing staff are advised during the treatment of acute-onset, severe hypertension.
- After initial stabilization, the team should monitor blood pressure closely and institute maintenance therapy as needed.
- Intravenous (IV) labetalol and hydralazine have long been considered first-line medications for the management of acute-onset, severe hypertension in pregnant women and women in the postpartum period.
- Immediate release oral nifedipine also may be considered as a first-line therapy, particularly when IV access is not available.
- The use of IV labetalol, IV hydralazine, or immediate release oral nifedipine for the treatment of acute-onset, severe hypertension for pregnant or postpartum patients does not require cardiac monitoring. Obstet Gynecol; ePub 2017 Mar 24; O’Neil Eckert, et al.
No comments:
Post a Comment